Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Paolo Strati(The University of Texas MD Anderson Cancer Center), Tom Chi(University of Calgary), Raphaël Steiner(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Simrit Parmar(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Misha Hawkins(The University of Texas MD Anderson Cancer Center), Sudhakar Tummala(The University of Texas MD Anderson Cancer Center), Sherry Adkins(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Shirley St. George, Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Lei Feng(Ministry of Public Security of the People's Republic of China), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Nicole Johnson, Haleigh Mistry, Catherine M. Claussen, Michael Wang(St. Joseph Health System), Prachee Singh, Charles Martinez, Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Sandra Horowitz(The University of Texas MD Anderson Cancer Center), Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center)
Cited by 114
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782